ADARx Pharmaceuticals (ADRX) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.85 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | XNCR |
|---|---|---|
| Share price | $17.33 | $24.26 |
| Market cap | $1.85B | $1.80B |
| 1-day change | -6.73% | -0.41% |
| YTD return | — | +58.46% |
| 1-year return | — | +101.66% |
| 5-year return | — | -36.94% |
| EPS (TTM) | $-1.16 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $30.61 |
| 52-week low | $17.20 | $10.38 |
| Distance from 52-week high | -25.33% | -20.74% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +29.51% |
| Average volume | 1.42M | 1.30M |
| Shares outstanding | 106.80M | 74.35M |
| Employees | 100 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Healthcare · Biotechnology · 100 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Healthcare · Biotechnology · 260 employees
ADRX vs XNCR FAQ
Which is bigger, ADARx Pharmaceuticals or Xencor?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.85B compared with $1.80B for Xencor (XNCR).
Are ADARx Pharmaceuticals and Xencor in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.